About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 410 record(s)
Req # A-2022-000492
Adverse Drug Reactions (ADRs) for CELEXA:. Report numbers: 00960723, 00965330, E2B_04427134, 00960155, E2B_04408157, 00957965, E2B_04584037, E2B_04567049, E2B_04619268, E2B_04588474.Organization: Health Canada
October 2022
Req # A-2022-000494
Adverse Drug Reactions (ADRs) for CIPRALEX. Report numbers: E2B_04456755, 957786, 959624, 969070, 970648, 965887, 970029, 964218, E2B_04645800, E2B_04630344.Organization: Health Canada
October 2022
Req # A-2022-000510
Adverse Drug Reaction (ADR) for DEFERIPRONE. Report number: E2B_01716613.Organization: Health Canada
October 2022
Req # A-2022-000521
Adverse Drug Reactions (ADRs). Report numbers: E2B_05200172, E2B_05186398, 000992656.Organization: Health Canada
October 2022
Req # A-2022-000523
Adverse Drug Reactions (ADRs). Report numbers: 000992364, 000994498.Organization: Health Canada
October 2022
Req # A-2022-000528
Adverse Drug Reactions (ADRs). Report numbers: E2B_02211131, E2B_02912148, E2B_02963835, E2B_03227597, E2B_03355369, E2B_03369173, E2B_03520116, E2B_03438670, E2B_03452860, E2B_03502886.Organization: Health Canada
October 2022
Req # A-2022-000532
Adverse Drug Reactions (ADRs). Report numbers: Adverse Drug Reactions (ADRs): E2B_00471053, E2B_05414160.Organization: Health Canada
October 2022
Req # A-2022-000533
Adverse Drug Reaction (ADR). Report number: E2B_05143310.Organization: Health Canada
October 2022
Req # A-2022-000549
Adverse Drug Reaction (ADR) for C1 ESTERASE INHIBITOR (HUMAN). Report number: E2B_05347402. ADR for CUVITRU. Report number: 000992706. ADRs for GAMMAGARD LIQUID. Report numbers: 000990508, 000992976, 000990937. ADRs for IMMUNOGLOBULIN (HUMAN). Report numbers: E2B_05338399, E2B_05336219, E2B_05338367, E2B_05326615, E2B_05314607.Organization: Health Canada
October 2022
Req # A-2022-000550
Adverse Drug Reactions (ADRs) for IMMUNOGLOBULIN (HUMAN). Report numbers: E2B_05401556, 000990511. ADR for IDURSULFASE. Report number: E2B_05359472. ADR for ICATIBANT (ICATIBANT ACETATE). Report number: E2B_05321269. ADR for AGALSIDASE ALFA. Report number: E2B_05370282. ADR for TAKHZYRO. Report number: E2B_05338593. ADRs for LANSOPRAZOLE. Report numbers: E2B_05327428, E2B_05387909.Organization: Health Canada
October 2022